2 weeks Ago By Defense World Staff
NewEdge Advisors LLC raised its position in shares of Thermo Fisher Scientific Inc. ( NYSE:TMO – Free Report ) by 7.8% in the second quarter, according to the company in its most recent 13F filing with the SEC.
The institutional investor owned 24,696 shares of the medical research company’s stock after purchasing an additional 1,784 shares during the quarter. NewEdge Advisors LLC’s holdings in Thermo Fisher Scientific were worth $13,657,000 as of its most recent SEC filing. Several other large investors have also modified their holdings of the stock.
Beaumont Financial Advisors LLC boosted its stake in shares of Thermo Fisher Scientific by 0.8% during the 1st quarter. Beaumont Financial Advisors LLC now owns 2,199 shares of the medical research company’s stock worth $1,278,000 after acquiring an additional 17 shares in the last quarter.
Cedar Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 14.5% in the first quarter. Cedar Wealth Management LLC now owns 134 shares of the medical research company’s stock valued at $78,000 after purchasing an additional 17 shares in the last quarter.
Lafayette Investments Inc. lifted its holdings in shares of Thermo Fisher Scientific by 2.1% in the second quarter.
Lafayette Investments Inc. now owns 830 shares of the medical research company’s stock valued at $459,000 after purchasing an additional 17 shares in the last quarter. Patrick M Sweeney & Associates Inc.
lifted its holdings in shares of Thermo Fisher Scientific by 1.8% in the second quarter. Patrick M Sweeney & Associates Inc.
now owns 1,031 shares of the medical research company’s stock valued at $570,000 after purchasing an additional 18 shares in the last quarter. Finally, Drive Wealth Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter.
Drive Wealth Management LLC now owns 2,123 shares of the medical research company’s stock valued at $1,175,000 after purchasing an additional 18 shares in the last quarter. 89.23% of the stock is owned by institutional investors.
Thermo Fisher Scientific Trading Down 0.8 % Shares of NYSE:TMO opened at $614.42 on Monday.
The company has a market cap of $234.53 billion, a P/E ratio of 39.41, a P/E/G ratio of 3.
88 and a beta of 0.78. The stock’s 50-day moving average is $606.
08 and its 200-day moving average is $581.88. Thermo Fisher Scientific Inc.
has a 52-week low of $415.60 and a 52-week high of $627.88.
The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.37 and a current ratio of 1.
72. Thermo Fisher Scientific Dividend Announcement The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be given a dividend of $0.
39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.
25%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.
01%. Wall Street Analysts Forecast Growth A number of research firms have recently issued reports on TMO. Bank of America increased their target price on Thermo Fisher Scientific from $600.
00 to $675.00 and gave the company a “buy” rating in a report on Monday, September 16th. Evercore ISI cut their price objective on Thermo Fisher Scientific from $615.
00 to $600.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Robert W.
Baird increased their price objective on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th.
Morgan Stanley increased their price objective on Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th.
Finally, Barclays cut their price objective on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating for the company in a report on Friday, June 28th.
Four analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $650.
41. View Our Latest Research Report on TMO Insider Buying and Selling In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, July 31st.
The stock was sold at an average price of $617.21, for a total transaction of $6,172,100.00.
Following the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $76,420,473.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link .
In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 3,624 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 26th. The stock was sold at an average price of $613.
02, for a total transaction of $2,221,584.48. Following the sale, the vice president now directly owns 13,699 shares of the company’s stock, valued at $8,397,760.
98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . Also, CEO Marc N.
Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.
00. Following the sale, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36.
The disclosure for this sale can be found here . Insiders have sold a total of 23,084 shares of company stock valued at $14,094,292 over the last three months. 0.
34% of the stock is owned by corporate insiders. Thermo Fisher Scientific Company Profile ( Free Report ) Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
See Also Five stocks we like better than Thermo Fisher Scientific 3 Grocery Stocks That Can Help Take a Bite Out of Inflation Simon Property REIT: A Safe Bet for Growth and Steady Dividends What does consumer price index measure? CarMax’s Impressive Rally: What Investors Should Watch Next Ride Out The Recession With These Dividend Kings MarketBeat Week in Review – 9/23 – 9/27 Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. ( NYSE:TMO – Free Report ).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter ..
